Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2…
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...
pharmaphorum4d
ESMO: Incyte's PD-1 treads new ground in anal cancer
Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel ...
FiercePharma5d
ESMO: Even after unique trial win, Incyte CEO views PD-1 drug Zynyz as pipeline aide
Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...
Business Wire7d
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
FiercePharma11d
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer
The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...
Targeted Oncology2d
Upfront Belrestotug and Dostarlimab Betters Responses in PD-L1–High NSCLC
The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated ...
oncnursingnews2d
Lung Cancer Trial Falls Short of Goal, But Presents Clinical Benefit in Some Patients
While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...
EurekAlert!24d
Research spotlight: Key regulators of pd-1 in melanoma cells and the immune system’s response
Immune checkpoint inhibitors are cancer fighting drugs that help the immune system do its job of detecting and attacking tumor cells. Programmed Cell Death 1 (PD-1) is a common target for this ...
pharmaphorum7mon
First patient treated with Moderna's PD-1/IDO1 cancer shot
PD-L1 is a cell ... with MSD’s PD-1 inhibitor Keytruda (pembrolizumab), a widely-used treatment for various cancers, including melanoma and non-small cell lung cancer (NSCLC), over six months.
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
This article Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 ...
Benzinga.com27d
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
The focus will be on whether these approvals should be restricted based on tumors' PD-L1 expression ... death cell ligand-1 (PD-L1) expression. Also Read: Merck Stops Lung Cancer Study For ...